Safe new therapy for genetic heart disease
A new clinical trial suggests that long-term use of candesartan, a drug currently used to treat hypertension, may significantly reduce the symptoms of genetic heart disease.
Drugmaker recalls deadly pain patch
Johnson & Johnson said Wednesday its PriCara division recalled two lots of the pain patch Duragesic, or fentanyl, because of tears in the products that could expose users directly to the product’s effective …
Innohep (tinzaparin sodium injection)
[UPDATE] Dear Healthcare Professional letter issued re: increased risk of death in elderly patients with renal insufficiency
Labopharm’s Ryzolt pain reliever approved by Food and Drug Administration
Investors in Labopharm Inc. held a New Year’s Eve celebration after the U.S. Food and Drug Administration approved Ryzolt, its once-daily formulation of painkiller tramadol.
Giant Stores Offering Free Antibiotics
Giant Food stores will offer free generic antibiotics to customers with a prescription for the next three months.
Possible Case: Dysport
Linked to Severe Birth Defects
PriCara Recalls 50 mcg/hr Duragesic (fentanyl transdermal system) CII Pain Patches
RARITAN, N.J., December 31, 2008 /PRNewswire/ — PriCara(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., said today that one lot of 50 microgram/hour (mcg/hr) DURAGESIC(R) (fentanyl transdermal system) CII patches sold by PriCara in the…
FDA Issues Weight Loss Pill Warning
Washngton, DC - The U.S. Food and Drug Administration is alerting consumers nationwide not to purchase or consume more than 25 different products marketed for weight loss because they contain undeclared, active …
Sinovac Announces that Government Investigation Rules Out Healive’s Role in Child’s Death
- Autopsy Results Show the Death was Caused by Myocarditis -
BEIJING, December 31, 2008 /PRNewswire-Asia/ — Sinovac Biotech Ltd. , a leading provider of vaccines in China, today provided an update regarding the suspension of the Company’s…
U.S. Navy Requested Operations Trial on FDA Hold
CAMBRIDGE, Mass., December 30, 2008 /PRNewswire-FirstCall/ — Biopure Corporation announced today that the Food and Drug Administration has advised the U.S. Naval Medical Research Center (”NMRC”) by letter that it may not initiate a clinical trial…